How to buy Soleno Therapeutics stock (SLNO)

Soleno Therapeutics is a biotechnology business based in the US. Soleno Therapeutics shares (SLNO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $45.18 – a decrease of 3.28% over the previous week. Soleno Therapeutics employs 33 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Soleno Therapeutics stock

Buy Soleno Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Soleno Therapeutics stock price (NASDAQ: SLNO)

Use our graph to track the performance of SLNO stocks over time.

Soleno Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$45.18
52-week range	$35.70 - $60.92
50-day moving average more info button	$53.26
200-day moving average more info button	$47.14
Wall St. target price	$74.25
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-2.79

Is it a good time to buy Soleno Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Soleno Therapeutics price performance over time

Historical closes compared with the close of $45.2 from 2024-12-19

1 week (2024-12-13)	-3.23%
1 month (2024-11-22)	-21.77%
3 months (2024-09-20)	-12.42%
6 months (2024-06-21)	9.84%

1 year (2023-12-22)	19.29%
2 years (2022-12-22)	2,974.83%
3 years (2021-12-22)	469.63%
5 years (2019-12-20)	74.18%

Soleno Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-48.05%
Return on equity TTM	-91.11%
Profit margin	0%
Book value	$6.45
Market Capitalization more info button	$2 billion

TTM: trailing 12 months

Soleno Therapeutics share dividends

We're not expecting Soleno Therapeutics to pay a dividend over the next 12 months.

Have Soleno Therapeutics's shares ever split?

Soleno Therapeutics's shares were split on a 1:15 basis on 25 August 2022 . So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Soleno Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Soleno Therapeutics shares which in turn could have impacted Soleno Therapeutics's share price.

Soleno Therapeutics share price volatility

Over the last 12 months, Soleno Therapeutics's shares have ranged in value from as little as $35.7 up to $60.92. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Soleno Therapeutics's is -1.439. This would suggest that Soleno Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Soleno Therapeutics has bucked the trend.

Soleno Therapeutics overview

Soleno Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc.

Frequently asked questions

What percentage of Soleno Therapeutics is owned by insiders or institutions?
Currently 3.047% of Soleno Therapeutics shares are held by insiders and 100.964% by institutions. How many people work for Soleno Therapeutics?
Latest data suggests 33 work at Soleno Therapeutics. When does the fiscal year end for Soleno Therapeutics?
Soleno Therapeutics's fiscal year ends in December. Where is Soleno Therapeutics based?
Soleno Therapeutics's address is: 203 Redwood Shores Parkway, Redwood City, CA, United States, 94065 What is Soleno Therapeutics's ISIN number?
Soleno Therapeutics's international securities identification number is: US8342032005 What is Soleno Therapeutics's CUSIP number?
Soleno Therapeutics's Committee on Uniform Securities Identification Procedures number is: 834203101